Journal of Clinical Densitometry
Volume 10, Issue 3 , Pages 259-265, July 2007

The Correction of BMD Measurements for Bone Strontium Content

  • Glen M. Blake

      Affiliations

    • Corresponding Author InformationAddress correspondence to: G.M. Blake, PhD, Department of Nuclear Medicine, King's College London School of Medicine, Guy's Hospital, St Thomas Street, London SE1 9RT, United Kingdom.
  • ,
  • Ignac Fogelman

King's College London School of Medicine, London, UK

Received 14 February 2007; accepted 29 March 2007. published online 02 June 2007.

Abstract 

Strontium ranelate (SR) is a new oral treatment for osteoporosis associated with large increases in bone mineral density (BMD) compared with alternative therapies such as bisphosphonates. Much of the BMD increase during SR treatment is a physical effect caused by the increased attenuation of X-rays due to the accumulation of strontium in bone tissue. The aim of this study was to assess the contribution made by bone strontium content (BSC) to the overall BMD increase by evaluating the percentage F of the BMD change explained by the physical presence of strontium in bone. A value of F less than 100% would provide evidence of the anabolic effect of SR as an additional factor contributing to the overall BMD increase. Studies of mixtures of strontium hydroxyapatite (SrHA) and calcium hydroxyapatite (CaHA) scanned on a variety of dual-energy X-ray absorptiometry (DXA) systems show that a 1% molar ratio of SrHA/(CaHA+SrHA) causes a 10% overestimation of BMD. The correction of spine BMD measurements for the physical effects of strontium depends on knowledge of 2 further factors: (1) bone biopsy measurements of iliac crest BSC and (2) the ratio R of BSC at the DXA site to BSC at the iliac crest measured in animal studies. We used clinical trial data and values of Rspine measured in studies of monkeys and beagle dogs to determine values of Fspine for 1, 2, and 3yr treatment with SR. Based on the average value of Rspine ∼0.7 for male and female monkeys, we found values for Fspine ∼75–80% for 1, 2, and 3yr of treatment. Using the value of Rspine ∼1.0 from the beagle study gave values of Fspine ∼100%. Although values of Fspine as low as 40% are possible, we conclude that the most likely figure is 75% or greater. However, it is apparent that there are large uncertainties in the correction of BMD results for the effect of bone strontium and that the most important of these is the inference of BSC values at DXA scan sites from measurements of iliac crest bone biopsy specimens.

Key Words: Bone mineral density, bone strontium content, osteoporosis, strontium ranelate

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1094-6950(07)00138-2

doi:10.1016/j.jocd.2007.03.102

Journal of Clinical Densitometry
Volume 10, Issue 3 , Pages 259-265, July 2007